|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/23/10 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/23/25 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 04/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 26/08/2016 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 572.55Cr | ||
| -0.82% | +1.40% | +39.64% | +143.17% | 1,27500Cr | ||
| -1.12% | +0.16% | +44.21% | +88.24% | 68TCr | ||
| -0.16% | +0.43% | +26.76% | +113.01% | 52TCr | ||
| -0.33% | +1.84% | +42.48% | +72.22% | 39TCr | ||
| -2.23% | -2.89% | +55.47% | +41.64% | 36TCr | ||
| -0.55% | +0.37% | +27.60% | +60.50% | 31TCr | ||
| -1.05% | +0.29% | +2.44% | +35.71% | 29TCr | ||
| -0.72% | -0.63% | +37.29% | +71.87% | 25TCr | ||
| -0.30% | -1.03% | +34.04% | +124.88% | 21TCr | ||
| Average | -0.72% | +0.26% | +34.44% | +83.47% | 43TCr | |
| Weighted average by Cap. | -0.82% | +0.76% | +36.61% | +97.62% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















